EVOLUTION AT MERCK - INVENTING FOR LIFE
HOSPITAL PORTFOLIO: OPTIMIZED BY
GLOBAL STRENGTH AND SCALE
bridion
Injection
(sugammadex) 100 mg/mL
* equivalent to 108.8 mg/mL sugammadex sodium
BRIDION poised for continued growth
worldwide as number of surgeries that
use a reversal agent increases
ZINPLAVA
(bezlotoxumab) 5mg/mL
Injection
PREVYMIS
(letermovir)
240 mg, 480 mg tablets
Injection 20 mg/mL
شده
ZERBAXA.
ceftolozane and tazobactam
for injection (1.5 g)
Sizable HAB/VAB pneumonia
indication represents new
opportunity for ZERBAXA growth
Pifeltro™
doravirine
100 mg tablets
Delstrigo™
doravirine/lamivudine/
tenofovir disoproxil fumarate
100 mg/300 mg/300 mg tablets
MERCK
INVENTING FOR LIFE
Leading portfolio of antibiotics and
antifungals, including novel products
Recent launches build on our HIV legacy
and further position us to bring next
generation treatments to market
Frank Clyburn
26View entire presentation